The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Ibuprofen Lysine · IBUPROFEN LYSINE 10 mg/mL · Solution · Intravenous · XGen Pharmaceuticals DJB, Inc.
NDC 39822-1030-02 · 3 VIAL in 1 CARTON / 2 mL in 1 VIAL · ANDA · View full market →
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Not scored — fragility is computed for NADAC-priced NDCs.
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Prasco Laboratories | IBUPROFEN LYSINE 10 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Recordati Rare Diseases Inc. | IBUPROFEN LYSINE 10 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| XGen Pharmaceuticals DJB, Inc. | IBUPROFEN LYSINE 10 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Ibuprofen Lysine — NDC 39822-1030-02," retrieved September 3, 2026, https://drugdashboards.com/drug/39822103002.
Free to cite with attribution — see how the data is put together.